Cliff Asness’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$165M Sell
2,266,489
-1,090,054
-32% -$70M 0.06% 452
2026
Q1
$186M Buy
3,356,543
+193,439
+6% +$12.6M 0.09% 321
2025
Q4
$254M Buy
3,163,104
+1,034,226
+49% +$69.5M 0.13% 198
2025
Q3
$103M Buy
2,128,878
+1,678,630
+373% +$104M 0.07% 409
2025
Q2
$33.4M Buy
450,248
+275,683
+158% +$18.3M 0.03% 658
2025
Q1
$10.9M Buy
174,565
+149,325
+592% +$10.2M 0.01% 845
2024
Q4
$1.95M Buy
25,240
+11,240
+80% +$903K ﹤0.01% 1549
2024
Q3
$1.13M Sell
14,000
-69,988
-83% -$5.65M ﹤0.01% 1777
2024
Q2
$6.95M Sell
83,988
-44,787
-35% -$3.94M 0.01% 883
2024
Q1
$10.9M Sell
128,775
-10,143
-7% -$796K 0.02% 693
2023
Q4
$11.9M Sell
138,918
-57,579
-29% -$4.98M 0.02% 639
2023
Q3
$17.6M Sell
196,497
-10,584
-5% -$945K 0.04% 509
2023
Q2
$17.6M Buy
207,081
+57,790
+39% +$4.89M 0.04% 513
2023
Q1
$12.3M Buy
149,291
+90,092
+152% +$7.29M 0.03% 613
2022
Q4
$4.64M Buy
59,199
+16,916
+40% +$1.36M 0.01% 930
2022
Q3
$3.13M Buy
42,283
+34,849
+469% +$2.5M 0.01% 1008
2022
Q2
$481K Sell
7,434
-18,279
-71% -$1.08M ﹤0.01% 1695
2022
Q1
$1.61M Buy
25,713
+18,704
+267% +$1.02M ﹤0.01% 1315
2021
Q4
$372K Sell
7,009
-62,216
-90% -$3.79M ﹤0.01% 1920
2021
Q3
$4.89M Sell
69,225
-21,870
-24% -$1.38M 0.01% 816
2021
Q2
$6.02M Buy
91,095
+56,287
+162% +$3.98M 0.01% 800
2021
Q1
$3.86M Sell
34,808
-22,706
-39% -$2.81M 0.01% 888
2020
Q4
$6.82M Sell
57,514
-23,527
-29% -$2.53M 0.01% 708
2020
Q3
$6.98M Buy
81,041
+22,640
+39% +$1.98M 0.01% 699
2020
Q2
$5.12M Buy
58,401
+14,964
+34% +$1.51M 0.01% 779
2020
Q1
$4.33M Sell
43,437
-108,264
-71% -$11.7M 0.01% 826
2019
Q4
$17.4M Sell
151,701
-147,400
-49% -$17.8M 0.02% 616
2019
Q3
$37.7M Sell
299,101
-372,530
-55% -$47.3M 0.04% 437
2019
Q2
$80.2M Sell
671,631
-411,879
-38% -$40.5M 0.09% 265
2019
Q1
$94.8M Buy
1,083,510
+215,054
+25% +$19.6M 0.1% 236
2018
Q4
$86.9M Buy
868,456
+420,673
+94% +$44.2M 0.1% 222
2018
Q3
$51.3M Buy
447,783
+270,157
+152% +$28M 0.05% 380
2018
Q2
$15.9M Buy
177,626
+82,213
+86% +$6.94M 0.02% 646
2018
Q1
$6.98M Buy
95,413
+84,057
+740% +$5.77M 0.01% 883
2017
Q4
$660K Buy
11,356
+6,592
+138% +$347K ﹤0.01% 1821
2017
Q3
$214K Buy
+4,764
New +$198K ﹤0.01% 2156
2017
Q2
Sell
-8,202
Closed -$333K 2210
2017
Q1
$333K Hold
8,202
﹤0.01% 1997
2016
Q4
$330K Sell
8,202
-37,687
-82% -$1.42M ﹤0.01% 2037
2016
Q3
$1.66M Buy
45,889
+2,530
+6% +$86.8K ﹤0.01% 1502
2016
Q2
$1.26M Buy
+43,359
New +$1.31M ﹤0.01% 1523
2015
Q4
Sell
-8,397
Closed -$271K 2263
2015
Q3
$271K Sell
8,397
-6,222
-43% -$234K ﹤0.01% 1956
2015
Q2
$605K Buy
+14,619
New +$616K ﹤0.01% 1704
2013
Q3
Sell
-6,200
Closed -$256K 2500
2013
Q2
$256K Buy
+6,200
New +$251K ﹤0.01% 2143

Other funds holding HAE

Cliff Asness's HAE Position: Q2 2026 in Review

Cliff Asness reduced its Haemonetics (HAE) stake by 32% in Q2 2026, selling an estimated $70M and leaving 2,266,489 shares worth $165M. The position accounts for 0.06% of the portfolio, ranked #452.

Cliff Asness first reported a position in HAE in Q2 2013 and has held it in 43 quarters since. The position peaked at $254M in Q4 2025. 327 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Cliff Asness held 2,266,489 shares of Haemonetics worth $165M as of Q2 2026.
  • Cliff Asness sold 1,090,054 Haemonetics shares in Q2 2026, an estimated $70M.
  • Haemonetics made up 0.06% of Cliff Asness's portfolio in Q2 2026, its #452 holding.
  • Cliff Asness first reported a position in Haemonetics in Q2 2013 and has held it in 43 quarters since.
  • Cliff Asness's Haemonetics position peaked at $254M in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.